SynthesisEuropean journal of nutrition2025
Assessing the genetic estimates of the association between plasma caffeine and cancer risk through Mendelian randomization.
Synthesis in European journal of nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Caffeine-mediated CD39Frontiers in immunology · 2026Article
- Plasma caffeine levels are not causally linked to the risk of lung cancer.European journal of nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObservational studies still cannot establish a causal relationship between plasma caffeine levels and cancer risk. This study aimed to investigate the genetic effects of plasma caffeine levels on cancer risk through Mendelian randomization (MR).
methodsPlasma caffeine's genome-wide association study (GWAS) data were derived from a meta-analysis of 9,876 individuals of European ancestry. We selected 8 single nucleotide polymorphisms (SNPs) closely associated with plasma caffeine levels as instrumental variables (IVs). The GWAS data for cancer outcomes were obtained from genotype data in the Finnish Biobank and digital health record data from the Finnish National Institute for Health and Welfare, specifically the R10 version released on December 18, 2023. The risk effects of genetic variations were assessed using the inverse variance-weighted (IVW) method and the wald ratio method.
resultsAfter correction, genetically predicted higher levels of plasma caffeine were significantly associated with an increased risk of lung cancer (OR = 1.54, 95%CI: 1.33-1.78, P_FDR < 0.001). In cancer subtype analysis, genetically predicted higher levels of plasma caffeine were significantly associated with the risk of lung squamous cell carcinoma (OR = 1.60, 95%CI: 1.16-2.19, P_FDR = 0.037) and non-small cell lung cancer (OR = 1.51, 95%CI: 1.21-1.89, P_FDR = 0.003) after correction.
conclusionThe current MR results indicate that long-term higher levels of plasma caffeine are associated with an increased risk of lung cancer. These findings merit further exploration to understand whether caffeine intake, supplementation, or cessation could have clinically relevant therapeutic or preventive effects.
Indexed as
Identifiers
40186783What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.